Takeda Pharmaceutical Co Ltd - Form 6-K Summary
Business Context and Reporting Period
This Form 6-K reports the resolutions passed at the 148th Ordinary General Meeting of Shareholders held on June 26, 2024. The filing covers matters reported on and resolved for the 147th fiscal year, which ran from April 1, 2023, to March 31, 2024.
Key Financial Metrics
The filing confirms the approval of the Appropriation of Surplus for the 147th fiscal year. The specific dividend declared is 94 yen (JPY94.00) per share. The filing references the Consolidated and Unconsolidated Financial Statements for the period but does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity within this document.
Material Changes
Material changes reported in this filing relate to corporate governance and capital distribution rather than operational financial performance:
- Dividend: Approval of a year-end dividend of 94 yen per share.
- Board Composition: Re-election of 8 non-Audit and Supervisory Committee Directors and new election of 2 (Milano Furuta and Emiko Higashi). Re-election of 3 Audit and Supervisory Committee Members and new election of 1 (Jean-Luc Butel).
- Executive Compensation: Approval of a bonus pool of up to 500 million yen for two specific Directors (excluding those residing outside Japan and External Directors).
Guidance, Outlook, and Risks
The filing does not contain management commentary, future guidance, outlook, risk factors, or contingencies. It is strictly a notice of shareholder meeting resolutions.
Investor Verification Checklist
- Verify the ex-dividend date and payment date for the approved 94 yen per share dividend.
- Review the full Consolidated Financial Statements for the 147th fiscal year (April 1, 2023 – March 31, 2024) referenced in the filing to obtain detailed revenue and profit figures.
- Confirm the specific identities of the two Directors eligible for the approved 500 million yen bonus pool.
- Check subsequent filings for the official appointment dates of the newly elected directors.